Klingenstein Fields & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Klingenstein Fields & Co’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-28,120	Closed	-$934K	–	224
2017 Q2	$934K	Hold	28,120	–	–	0.04%	132
2017 Q1	$902K	Sell	28,120 -7,191	-20%	-$245K	0.04%	133
2016 Q4	$1.28M	Sell	35,311 -69,643	-66%	-$2.78M	0.06%	120
2016 Q3	$4.83M	Sell	104,954 -87,893	-46%	-$4.59M	0.22%	70
2016 Q2	$9.69M	Buy	192,847 +38,322	+25%	+$2.04M	0.45%	55
2016 Q1	$8.27M	Buy	154,525 +149,145	+2,772%	+$8.75M	0.41%	57
2015 Q4	$353K	Hold	5,380	–	–	0.02%	169
2015 Q3	$304K	Hold	5,380	–	–	0.02%	179
2015 Q2	$318K	Hold	5,380	–	–	0.01%	193
2015 Q1	$335K	Hold	5,380	–	–	0.01%	191
2014 Q4	$309K	Sell	5,380 -60	-1%	-$3.34K	0.01%	197
2014 Q3	$292K	Sell	5,440 -800	-13%	-$42.4K	0.01%	203
2014 Q2	$327K	Buy	6,240 +140	+2%	+$7.16K	0.01%	202
2014 Q1	$322K	Sell	6,100 -1,100	-15%	-$50.8K	0.01%	205
2013 Q4	$289K	Hold	7,200	–	–	0.01%	263
2013 Q3	$272K	Sell	7,200 -1,500	-17%	-$58.5K	0.01%	262
2013 Q2	$341K	Buy	+8,700	New	+$339K	0.01%	248

Other funds holding TEVA

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Klingenstein Fields & Co's TEVA Position: Q3 2017 in Review

Klingenstein Fields & Co sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 28,120 shares — an estimated $934K sold.

Klingenstein Fields & Co first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $9.69M in Q2 2016. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Klingenstein Fields & Co reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Klingenstein Fields & Co sold 28,120 Teva Pharmaceuticals shares in Q3 2017, an estimated $934K.
Klingenstein Fields & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
Klingenstein Fields & Co's Teva Pharmaceuticals position peaked at $9.69M in Q2 2016.
537 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Klingenstein Fields & Co's 13F filing for Q3 2017, filed 1 Nov 2017.